Varicose veins (VVs) have a high prevalence worldwide and have become a major medical burden. Their pathophysiology involves a complex interplay of inflammation and tissue remodeling, and current treatment is limited by its impact on the pathophysiological mechanisms. In addition, despite clear environmental factors, family history is an important risk factor, suggesting a genetic component to the risk of developing VVs. Our understanding of the pathogenesis of these diseases has benefited greatly from the expansion of population genetic studies, from pioneering family studies to large genome-wide association studies; we now find multiple risk loci for each venous disease. This review considers the pathophysiology of VVs, highlighting the current state of genetic knowledge. We also propose future directions for research.
RabeEPannierF. [What is evidence-based in the treatment of chronic venous insufficiency?]. Internist. 2020;61(12):1230-7.
3.
YounYJLeeJ. Chronic venous insufficiency and varicose veins of the lower extremities. Korean J Intern Med. 2019;34(2):269-283.
4.
SmetaninaMAKelAESevost’IanovaKS, et al.DNA methylation and gene expression profiling reveal MFAP5 as a regulatory driver of extracellular matrix remodeling in varicose vein disease. Epigenomics. 2018;10(8):1103-1119.
5.
ShadrinaAVoroninaESmetaninaM, et al.Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians. Immunol Res. 2018;66(1):141-150.
6.
SoláLRAcevesMDueñasAI, et al.Varicose veins show enhanced chemokine expression. Eur J Vasc Endovasc Surg. 2009;38(5):635-641.
7.
ElsharawyMANaimMMAbdelmaguidEMAl-MulhimAA. Role of saphenous vein wall in the pathogenesis of primary varicose veins. Interact Cardiovasc Thorac Surg. 2007;6(2):219-224.
HsiehCSTsaiCTChenYH, et al.Global expression profiling identifies a novel Hyaluronan synthases 2 gene in the pathogenesis of lower extremity varicose veins. J Clin Med. 2018;7(12):537.
12.
NaoumJJHunterGCWoodsideKJChenC. Current advances in the pathogenesis of varicose veins. J Surg Res. 2007;141(2):311-6.
13.
OrtegaMARomeroBAsunsoloA, et al.Behavior of smooth muscle cells under hypoxic conditions: possible implications on the varicose vein endothelium. BioMed Res Int. 2018;2018:7156150.
14.
GuoZZhangWLiXWangTYangXFanL. Biomechanical stretch-induced CLOCK upregulation in venous smooth muscle cells promotes phenotypic and functional transformation. Vascul Pharmacol. 2022;146:107097.
15.
UrbanekTSkopBWiaderkiewiczR, et al.Smooth muscle cell apoptosis in primary varicose veins. Eur J Vasc Endovasc Surg. 2004;28(6):600-61.
16.
GuoZLuoCZhuTLiLZhangW. Elevated c-fos expression is correlated with phenotypic switching of human vascular smooth muscle cells derived from lower limb venous varicosities. J Vasc Surg Venous Lymphat Disord. 2021;9(1):242-251.
17.
KnaapenMWSomersPBortierHDe MeyerGRKockxMM. Smooth muscle cell hypertrophy in varicose veins is associated with expression of estrogen receptor-beta. J Vasc Res. 2005;42(1):8-12.
18.
KumarPKhanIADasAShahH. Chronic venous disease. Part 1: pathophysiology and clinical features. Clin Exp Dermatol. 2022;47(7):1228-1239.
19.
LimCSGohelMSShepherdACPaleologEDaviesAH. Venous hypoxia: a poorly studied etiological factor of varicose veins. J Vasc Res. 2011;48(3):185-194.
20.
Sousa FialhoMLAbd JamilAHStannardGAHeatherLC. Hypoxia-inducible factor 1 signalling, metabolism and its therapeutic potential in cardiovascular disease. Biochim Biophys Acta, Mol Basis Dis. 2019;1865(4):831-43.
21.
KimGDNgHPChanERMahabeleshwarGH. Macrophage-hypoxia-inducible factor-1α signaling in carotid artery stenosis. Am J Pathol. 2021;191(6):1118-1134.
22.
GhaderianSMLindseyNJGrahamAMHomer-VanniasinkamSAkbarzadeh NajarR. Pathogenic mechanisms in varicose vein disease: the role of hypoxia and inflammation. Pathology. 2010;42(5):446-53.
23.
Castro-FerreiraRCardosoRLeite-MoreiraAMansilhaA. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380-393.
24.
SegietOABrzozowa-ZasadaMPiecuchADudekDReichman-WarmuszEWojniczR. Biomolecular mechanisms in varicose veins development. Ann Vasc Surg. 2015;29(2):377-84.
25.
VodovotzLZamoraRBarclayDA, et al.Inflammatory signals and network connections implicate cell-mediated immunity in chronic venous insufficiency. Ann Transl Med. 2021;9(22):1643.
26.
RaffettoJD. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res. 2009;123(Suppl 4):S66-S71.
27.
CallesenKTMogrenSBerlinF, et al.Characterization of mast cells from healthy and varicose human saphenous vein. Biomedicines. 2022;10(5):1062.
28.
TiwarySKKumarAMishraSPKumarPKhannaAK. Study of association of varicose veins and inflammation by inflammatory markers. Phlebology. 2020; 35(9):679-685.
29.
LattimerCRKalodikiEGeroulakosGHoppensteadtDFareedJ. Are inflammatory biomarkers increased in varicose vein blood?Clin Appl Thromb Hemost. 2016;22(7):656-664.
30.
BurianEASabahLKarlsmarkT, et al.Cytokines and venous leg ulcer healing-A systematic review. Int J Mol Sci. 2022;23(12):6526. Published 2022 Jun 10.
31.
ZhangJNieQSiC, et al.Weighted gene Co-expression network analysis for RNA-sequencing data of the varicose veins transcriptome. Front Physiol. 2019;10:278.
32.
GouWWangXWangLWangKChenS. Correlation of TNF-α, Cys C, and NLRP3 inflammasomes with venous ulcers in patients with lower extremity varicose veins. Am J Transl Res. 2023;15(2):1186-1194.
33.
PfistererLKonigGHeckerMKorffT. Pathogenesis of varicose veins - lessons from biomechanics. Vasa. 2014;43(2):88-99.
34.
ChiuJJChienS. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91(1):327-387.
PolkTSchmittSAldrichJLLongDS. Human dermal microvascular endothelial cell morphological response to fluid shear stress. Microvasc Res. 2022;143:104377.
37.
ChandranLKSreekumarABeenaV, et al.Shear stress alterations activate BMP4/pSMAD5 signaling and induce endothelial mesenchymal transition in varicose veins. Cells. 2021;10(12):3563.
38.
BaeyensNBandyopadhyayCCoonBGYunSSchwartzMA. Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest. 2016;126(3):821-828.
39.
RecekC. The hemodynamic paradox as a phenomenon triggering recurrent reflux in varicose vein disease. Int J Angiol. 2012;21(3):181-6.
40.
MutlakOAslamMStandfieldNJ. Chronic venous insufficiency: a new concept to understand pathophysiology at the microvascular level - a pilot study. Perfusion. 2019;34(1):84-9.
41.
BerganJMolecular mechanisms in chronic venous insufficiency. Ann Vasc Surg. 2007;21(3):260-266.
42.
OrtegaMAFraile-MartinezOGarcia-MonteroC, et al.Understanding chronic venous disease: a critical overview of its pathophysiology and medical management. J Clin Med. 2021;10(15):3239.
43.
LabropoulosN. How does chronic venous disease progress from the first symptoms to the advanced stages? A review. Adv Ther. 2019;36(Suppl 1):13-19.
44.
AslamMRMuhammad AsifHAhmadK, et al.Global impact and contributing factors in varicose vein disease development. Sage Open Med. 2022;10:20503121221118992.
45.
JianHPoetschA. CASZ1: current implications in cardiovascular diseases and cancers. Biomedicines. 2023;11(7):2079. Published 2023 Jul 24.
46.
HeRCaiHJiangY, et al.Integrative analysis prioritizes the relevant genes and risk factors for chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2022;10(3):738-748.e5.
47.
YokotaKShibataHKuriharaIKobayashiSMurai-TakedaAItohH. CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor. Hypertens Res. 2021;44(4):407-416.
48.
ShadrinaATsepilovYSmetaninaM, et al.Polymorphisms of genes involved in inflammation and blood vessel development influence the risk of varicose veins. Clin Genet. 2018;94(2):191-199.
49.
CharpentierMSTaylorJMConlonFL. The CASZ1/Egfl7 transcriptional pathway is required for RhoA expression in vascular endothelial cells. Small GTPases. 2013;4(4):231-5.
50.
BhaskaranNLiuZSaravanamuthuSS, et al.Identification of Casz1 as a regulatory protein controlling T helper cell differentiation, inflammation, and immunity. Front Immunol. 2018;9:184.
51.
CosteBMathurJSchmidtM, et al.Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010;330(6000):55-60.
52.
LiJHouBTumovaS, et al.Piezo1 integration of vascular architecture with physiological force. Nature. 2014;515(7526):279-282.
53.
WangSChennupatiRKaurHIringAWettschureckNOffermannsS. Endothelial cation channel PIEZO1 controls blood pressure by mediating flow- induced ATP release. J Clin Invest. 2016;126(12):4527-4536.
54.
WangZChenJBabichevaA, et al.Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension. Am J Physiol Cell Physiol. 2021;321(6):C1010-C1027.
55.
RecekC. Venous pressure gradients in the lower extremity and the hemodynamic consequences. Vasa. 2010;39(4):292-297.
56.
RodeBShiJEndeshN, et al.Piezo1 channels sense whole body physical activity to reset cardiovascular homeostasis and enhance performance. Nat Commun. 2017;8(1):350.
57.
BeechDJKalliAC. Force sensing by Piezo channels in cardiovascular health and disease. Arterioscler Thromb Vasc Biol. 2019;39(11):2228-2239.
58.
Van HoutCVTachmazidouIBackmanJD, et al.Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature. 2020;586(7831):749-756.
59.
SmelserDTHaleyJSRyerEJElmoreJRCookAMCareyDJ. Association of varicose veins with rare protein-truncating variants in PIEZO1 identified by exome sequencing of a large clinical population. J Vasc Surg Venous Lymphat Disord. 2022;10(2):382-389.e2.
60.
HansonEHImperatoreGBurkeW. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001;154(3):193-206.
61.
BartonJCEdwardsCQActonRT. HFE gene: structure, function, mutations, and associated iron abnormalities. Gene. 2015;574(2):179-92.
62.
SokolovaEAShadrinaASSevost’IanovaKS, et al.HFE p.C282Y gene variant is associated with varicose veins in Russian population. Clin Exp Med. 2016;16(3):463-70.
63.
ZamboniPTognazzoSIzzoM, et al.Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg. 2005;42(2):309-14.
64.
RaffettoJDLigiDManiscalcoRKhalilRAMannelloF. Why venous leg ulcers have difficulty healing: overview on pathophysiology, clinical consequences, and treatment. J Clin Med. 2020;10(1):29.
65.
Shapouri-MoghaddamAMohammadianSVaziniH, et al.Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425-6440.
ZamboniPGemmatiD. Clinical implications of gene polymorphisms in venous leg ulcer: a model in tissue injury and reparative process. Thromb Haemostasis. 2007;98(1):131-137.
68.
MelincoviciCSBoscaABSusmanS, et al.Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455-467.
ApteRSChenDSFerraraN. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248-1264.
71.
ShadrinaASSmetaninaMASokolovaEA, et al.Allele rs2010963 C of the VEGFA gene is associated with the decreased risk of primary varicose veins in ethnic Russians. Phlebology. 2018;33(1):27-35.
72.
Al-ZoubiNAYaghanRJMazahrehTS, et al.Evaluation of plasma growth factors (VEGF, PDGF, EGF, ANG1, and ANG2) in patients with varicose veins before and after treatment with endovenous laser ablation. Photomed Laser Surg. 2018;36(3):169-173.
XuLWillumeit-RomerRLuthringer-FeyerabendB. Effect of magnesium-degradation products and hypoxia on the angiogenesis of human umbilical vein endothelial cells. Acta Biomater. 2019;98:269-283.
75.
SerraRBracaleUMChilàC, et al.Clinical and pathological correlations in chronic venous disease. Ann Vasc Surg. 2022;78:19-27.
76.
CuiNHuMKhalilRA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1-73.
77.
BassiouniWAliMAMSchulzR. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J. 2021;288(24):7162-7182.
DeatrickKBEliasonJLLynchEM, et al.Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg. 2005;42(1):140-148.
80.
NagaseHVisseRMurphyG. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573.
81.
ArpinoVBrockMGillSE. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015;44-46:247-254.
82.
Cabral-PachecoGAGarza-VelozICastruita-De la RosaC, et al.The roles of matrix metalloproteinases and their Inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739.
83.
HuXHuFXuYTangJChuHZhongY. Disequilibrium in MMPs and the tissue inhibitor of metalloproteinases in different segments of the varicose great saphenous vein wall. Int Angiol. 2019;38(3):185-193.
84.
YanLTangJHuX, et al.Imbalance in matrix metalloproteinases and tissue inhibitor of metalloproteinases from splenic veins and great saphenous veins under high hemodynamics. Phlebology. 2020;35(1):18-26.
85.
EsfandiariGBiranvandASPoursalehA, et al.Effect of a peptide construct on differentiated macrophage MMP-2 and MMP-9 levels of varicose patients. Curr Pharmaceut Des. 2019;25(40):4303-4309.
86.
AnbarasanCBavanilathaMLatchumanadhasKAjit MullasariS. ICAM-1 molecular mechanism and genome wide SNP's association studies. Indian Heart J. 2015;67(3):282-7.
87.
CybulskyMIFriesJWWilliamsAJ, et al.Gene structure, chromosomal location, and basis for alternative mRNA splicing of the human VCAM1 gene. Proc Natl Acad Sci USA. 1991;88(17):7859-63.
88.
van BuulJDvan RijsselJvan AlphenFPvan StalborchAMMulEPHordijkPL. ICAM-1 clustering on endothelial cells recruits VCAM-1. J Biomed Biotechnol. 2010;2010:120328.
89.
BuiTMWiesolekHLSumaginR. ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 2020;108(3):787-799.
90.
TroncosoMFOrtiz-QuinteroJGarrido-MorenoV, et al.VCAM-1 as a predictor biomarker in cardiovascular disease. Biochim Biophys Acta, Mol Basis Dis. 2021;1867(9):166170.
91.
BirdinaJPilmaneMLigersA. The morphofunctional changes in the wall of varicose veins. Ann Vasc Surg. 2017;42:274-284.
92.
Mikula-PietrasikJUruskiPAniukiewiczK, et al.Serum from varicose patients induces senescence-related dysfunction of vascular endothelium generating local and systemic proinflammatory conditions. Oxid Med Cell Longev. 2016;2016:2069290.
93.
LangPPBaiJZhangYL, et al.Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction. Lab Invest. 2020;100(3):378-386.
94.
TroncosoMFDíaz-VesgaMCSanhueza-OlivaresF, et al.Targeting VCAM-1: a therapeutic opportunity for vascular damage. Expert Opin Ther Targets. 2023;27(3):207-223.
95.
ZhuH. Forkhead box transcription factors in embryonic heart development and congenital heart disease. Life Sci. 2016;144:194-201.
96.
XiaSMendenHLKorfhagenTRKumeTSampathV. Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling. J Physiol. 2018;596(8):1397-1417.
97.
SeoSFujitaHNakanoAKangMDuarteAKumeT. The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev Biol. 2006;294(2):458-70.
98.
SurendranSGirijammaANairR, et al.Forkhead box C2 promoter variant c.-512C>T is associated with increased susceptibility to chronic venous diseases. Plos One. 2014;9(3):e90682.
99.
NgMYAndrewTSpectorTDJefferySLymphoedema Consortium. Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. J Med Genet. 2005;42(3):235-9.
100.
LyonsOSahaPSeetC, et al.Human venous valve disease caused by mutations in FOXC2 and GJC2. J Exp Med. 2017;214(8):2437-2452.
101.
MungerSJGengXSrinivasanRSWitteMHPaulDLSimonAM. Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice. Dev Biol. 2016;412(2):173-90.
102.
MellorRHBriceGStantonAW, et al.Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation. 2007;115(14):1912-1920.
103.
ZhangCLiHGuoX. FOXC2-AS1 regulates phenotypic transition, proliferation and migration of human great saphenous vein smooth muscle cells. Biol Res. 2019;52(1):59.
104.
CaoYCaoZWangWJieXLiL. MicroRNA199a5p regulates FOXC2 to control human vascular smooth muscle cell phenotypic switch. Mol Med Rep. 2021;24(3):627.
105.
AliTGroteP. Beyond the RNA-dependent function of LncRNA genes. Elife. 2020;9:e60583.
106.
WuTDuY. LncRNAs: from basic research to medical application. Int J Biol Sci. 2017;13(3):295-307.
107.
BridgesMCDaulagalaACKourtidisA. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2):e202009045.
108.
LiXJiangXYGeJ, et al.Aberrantly expressed lncRNAs in primary varicose great saphenous veins. Plos One. 2014;9(1):e86156.
109.
LiLLiXTheE, et al.Low expression of lncRNA-GAS5 is implicated in human primary varicose great saphenous veins. PLoS One. 2015;10(3):e0120550.
110.
YeBWuZHTsuiTY, et al.lncRNA KCNQ1OT1 suppresses the inflammation and proliferation of vascular smooth muscle cells through IκBa in intimal hyperplasia. Mol Ther Nucleic Acids. 2020;20:62-72.
111.
XueYZLiZJLiuWTShanJJWangLSuQ. Down-regulation of lncRNA MALAT1 alleviates vascular lesion and vascular remodeling of rats with hypertension. Aging (Albany NY). 2019;11(14):5192-5205.
112.
WeiJZhuHZhangQZhangQ. Prediction of functional genes in primary varicose great saphenous veins using the lncRNA-miRNA-mRNA network. Comput Math Methods Med. 2022;2022:4722483.
113.
HelkkulaPHassanSSaarentausE, et al.Genome-wide association study of varicose veins identifies a protective missense variant in GJD3 enriched in the Finnish population. Commun Biol. 2023;6(1):71.
114.
LeeMLLiangCChuangCH, et al.A genome-wide association study for varicose veins. Phlebology. 2022;37(4):267-278.
115.
LiSLiuYLiuMWangLLiX. Comprehensive bioinformatics analysis reveals biomarkers of DNA methylation-related genes in varicose veins. Front Genet. 2022;13:1013803.
116.
AhmedWUKleemanSNgM, et al.Genome-wide association analysis and replication in 810,625 individuals with varicose veins. Nat Commun. 2022;13(1):3065.
117.
ShadrinaASElgaevaEEStanawayIB, et al.Mendelian randomization analysis of plasma levels of CD209 and MICB proteins and the risk of varicose veins of lower extremities. PLoS One. 2022;17(5):e0268725.
118.
AmatoRDattiloVBresciaC, et al.Th17-Gene expression profile in patients with chronic venous disease and venous ulcers: genetic modulations and preliminary clinical evidence. Biomolecules. 2022;12(7):902.
119.
LeeAJRobertsonLABoghossianSM, et al.Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18-26.
120.
LalBK. Venous ulcers of the lower extremity: definition, epidemiology, and economic and social burdens. Semin Vasc Surg. 2015;28(1):3-5.
121.
DaviesAH. The seriousness of chronic venous disease: a review of real-world evidence. Adv Ther. 2019;36(Suppl 1):5-12.
122.
RusinovichYRusinovichV. Association between right heart diastolic function and clinical presentation of chronic venous disease and primary varicose veins of lower extremities. Phlebology. 2020;35(7):513-519.
123.
RusinovichYRusinovichV. Cardiac response to changes in central venous sonomorphology: mechanism of impaired heart relaxation in patients with varicose veins of lower extremities. Phlebology. 2022;37(9):644-650.
124.
HuWSLinCL. Association between varicose vein and atrial fibrillation-a population-based study in Taiwan. Phlebology. 2022;37(7):535-539.
125.
PoredosPKozakMAntignaniPLJezovnikMK. From varicose veins to venous thromboembolic events. Int Angiol. 2023;42(3):254-259.
126.
ChangSLHuangYLLeeMC, et al.Association of varicose veins with incident venous thromboembolism and peripheral artery disease. JAMA. 2018;319(8):807-17.
127.
LiRChenZGuiL, et al.Varicose veins and risk of venous thromboembolic diseases: a two-sample-based Mendelian randomization study. Front Cardiovasc Med. 2022;9:849027. Published 2022 Apr 14.
128.
BaylisRASmithNLKlarinDFukayaE. Epidemiology and genetics of venous thromboembolism and chronic venous disease. Circ Res. 2021;128(12):1988-2002.
129.
ChengCY. Increased incident Alzheimer’s disease among individuals with varicose veins: a population-based cohort study. J Prev Alzheimers Dis. 2022;9(3):441-448.
